Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
S-1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy. |
| Name | Type | Description |
|---|---|---|
| DOCETAXEL | DRUG | 50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles. |
| S-1 | DRUG | 80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year. |
| OXALIPLATIN | DRUG | 100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles. |
Inclusion criteria: * Patients with histologically confirmed, newly diagnosed, localized gastric or gastro-esophageal adenocarcinoma, that is considered operable. * The bulk of disease must be localized in the stomach, although the gastroesophageal junction may be involved. * Patients with T3 ...
Top 20 of 45 competitors
S-1 is an investigational small molecule being studied for the treatment of gastric cancer. It is being evaluated in combination with docetaxel and oxaliplatin in patients with potentially operable gastric or gastroesophageal adenocarcinoma. The drug is still in clinical development and is not approved.
S-1 is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 2 clinical development for gastric cancer.
S-1 is in Phase 2 clinical development for gastric cancer. It has completed one Phase 2 trial, and the drug remains investigational. It has not been approved by regulatory authorities.
S-1 has been studied in a completed Phase 2 clinical trial with the identifier NCT00816543. The trial evaluated docetaxel plus oxaliplatin plus S-1 in patients with potentially operable gastric or gastroesophageal adenocarcinoma. The study enrolled 41 participants in South Korea.
S-1 is the drug name used in clinical development. No alternative names have been established for this drug in the available information. It is being studied under the name S-1 in the context of gastric cancer treatment.